ACXP
Acurx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.42
+1.43%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- +23.5%
- EPS
- +67.0%
- Free cash flow
- +24.2%
- Operating cash flow
- +24.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +55.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- +42.6%
- Net income
- +43.5%
- EPS
- +69.8%
- Free cash flow
- +34.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026